- Home
- PTN
as 04-01-2025 3:41pm EST
Palatin Technologies Inc is a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system. The product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.
| Founded: | 1986 | Country: | United States |
| Employees: | N/A | City: | CRANBURY |
| Market Cap: | 20.9M | IPO Year: | 1993 |
| Target Price: | $7.00 | AVG Volume (30 days): | 858.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.49 - $2.88 | Next Earning Date: | 05-14-2025 |
| Revenue: | $350,000 | Revenue Growth: | -95.07% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Palatin Technologies Inc. News
PTN Breaking Stock News: Dive into PTN Ticker-Specific Updates for Smart Investing
PR Newswire
2 days ago
Palatin Announces MC4R Agonist Bremelanotide Co-Administered with GLP-1/GIP Tirzepatide Meets Primary Endpoint in Phase 2 Obesity Study
Clinical Trials Arena
5 days ago
Palatin’s UC therapy prompts clinical remission in a third of patients
MT Newswires
5 days ago
Palatin Technologies' Ulcerative Colitis Drug Candidate Shows Positive Results in Phase 2 Study
PR Newswire
5 days ago
Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177
PR Newswire
8 days ago
Palatin's Oral MC4R Agonist PL7737 Receives FDA Orphan Drug Designation for Obesity Due to Leptin Receptor Deficiency
Zacks
20 days ago
Here's Why Palatin Technologies (PTN) Is a Great 'Buy the Bottom' Stock Now
Thomson Reuters StreetEvents
2 months ago
Q2 2025 Palatin Technologies Inc Earnings Call
GuruFocus.com
2 months ago
Palatin Technologies Inc (PTN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ...
Compare PTN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PTN Palatin Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.